Zai Lab (ZLAB) Competitors

Zai Lab (NASDAQ:ZLAB) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Do institutionals and insiders hold more shares of ZLAB or GMAB?

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 13.9% of Zai Lab shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has preferable valuation & earnings, ZLAB or GMAB?

Genmab A/S has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$398.99M	8.35	-$334.62M	-$2.59	-11.73
Genmab A/S	$21.53B	0.60	$1.14B	$1.74	11.21

Is ZLAB or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Zai Lab's net margin of -76.14%. Genmab A/S's return on equity of 16.78% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-76.14%	-36.97%	-27.10%
Genmab A/S	36.30%	16.78%	13.79%

Do analysts recommend ZLAB or GMAB?

Zai Lab currently has a consensus target price of $47.37, suggesting a potential upside of 55.91%. Genmab A/S has a consensus target price of $39.17, suggesting a potential upside of 100.75%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Does the MarketBeat Community prefer ZLAB or GMAB?

Zai Lab received 64 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 64.53% of users gave Zai Lab an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 231 64.53%	Underperform Votes 127 35.47%
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%

Which has more risk and volatility, ZLAB or GMAB?

Zai Lab has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Does the media favor ZLAB or GMAB?

In the previous week, Genmab A/S had 7 more articles in the media than Zai Lab. MarketBeat recorded 23 mentions for Genmab A/S and 16 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.79 beat Genmab A/S's score of 0.72 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Zai Lab on 11 of the 19 factors compared between the two stocks.